Research on Patients With Heart Transplantation

Status Active, not recruiting

Clinical Trial Summary

This trial was a single-center, prospective cohort study.The purpose of this clinical research is to evaluate the accuracy of combining multimodality MR Imaging with circulating exosomal miRNA expression to diagnose acute rejection in patients with heart transplantation，thus it may be helpful for timely intervention to improve the patient's prognosis.

Clinical Trial Description

Acute rejection (AR) after heart transplantation remains the major factor limiting long-term survival, and an independent risk factor for chronic allograft vasculopathy. Currently, there remains no reliable non-invasive method to detect AR. Multimodality magnetic resonance (MR) imaging shows accurate detection of myocardial damage, such as interstitial cell infiltrates, edema, hemorrhage, myocyte damage/necrosis and capillary stenosis or fragmentation. It turned out that the indicators in both MR imaging and circulating exosomal miRNA showed difference between patients with and without AR in our initial research work. Therefore, we hypothesize that circulating exosomal miRNA may play an important role in the activation of signaling pathway in AR after heart transplantation, which can be detected by multimodality MR imaging. All transplant recipients receiving transplantation follow-up care in our center were approached. In the present research we aim to combine multimodality MR imaging with circulating exosomal miRNA to explore a new evaluation methodology and platform for early and noninvasive detection of AR after heart transplantation. We attempt to confirm contribution of circulating exosomal miRNA to myocardial damage of AR through biopsy-proven allograft rejection and animal heterotopic heart transplantation. ;

Study Design

Related Conditions & MeSH terms

Heart Transplant Rejection

Clinical Trial Details

NCT number	NCT04921774
Study type	Observational
Source	Guangdong Provincial People's Hospital
Contact
Status	Active, not recruiting
Phase
Start date	January 1, 2020
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05205551` - Prospera Test Evaluation in Cardiac Transplant (ProTECT)
Not yet recruiting	`NCT05732779` - Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients	N/A
Active, not recruiting	`NCT05064462` - TTV Viral Load in Heart Transplant Recipients
Recruiting	`NCT04973943` - Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
Completed	`NCT03477383` - A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
Not yet recruiting	`NCT05772442` - Cardiac Transplant Metabolomics With and Without Rejection
Recruiting	`NCT04707872` - Trifecta-Heart cfDNA-MMDx Study
Recruiting	`NCT06064123` - Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
Recruiting	`NCT04226521` - Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy	N/A
Completed	`NCT03393793` - HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Completed	`NCT01136135` - Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection	N/A
Completed	`NCT03833050` - The TOGETHER Project - Heart
Active, not recruiting	`NCT03373227` - Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen	Phase 2
Active, not recruiting	`NCT03695601` - Surveillance HeartCare® Outcomes Registry
Active, not recruiting	`NCT01397812` - Heartsbreath Test for Heart Transplant Rejection	N/A
Active, not recruiting	`NCT05184426` - MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)